| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 6.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Neurostimulation Devices Market Analysis
The Europe Neurostimulation Market is expected to register a CAGR of 6.1% during the forecast period.
The major factors for the growth of the European neurostimulation market include the growth in the geriatric population and rising prevalence of neurological disorders, increasing demand for minimally invasive surgeries, and technological advancements.
Among the age-related neurodegenerative disorders, Parkinson's disease (PD) is the second-most common, after Alzheimer's disease. According to NHS UK, Parkinson's disease affects around 1 in 500 people. Hence, there are an estimated 127,000 people in the United Kingdom, who are currently living with the condition. Most people with Parkinson's start to develop symptoms when they're over 50, although around 1 in 20 people with the condition, first experience symptoms when they're under 40. Furthermore, neurostimulation devices also play a significant role in pain management. In November 2018, Abbott announced the launch of the new DRG Invisible Trial System, which is approved by the US Food and Drug Administration (FDA) and has received the CE Mark in Europe. Thus, owing to the rising prevalence of neurological diseases and increasing technological advancements, the market is expected to witness high growth over the forecast period.
Europe Neurostimulation Devices Market Trends
Parkinson’s Disease Segment is expected to be the Fastest Growing Segment
With the growing aging population and increasing prevalence of Parkinson's disease, the market is expected to witness a high growth rate. Parkinson's syndrome is one of the most common neurological diseases found in Germany. It is found to be affecting the older population, and among people aged above 65 years, the prevalence is 1,800 per 100,000. Therefore, in Germany, the number of patients is likely to increase in the future. Furthermore, Europe has a growing aging population. For instance, according to the Fondation de France, one in five French person is over 60 years old, and in 2050 one in three will be. Therefore age-associated diseases are assuming ever-greater proportions. Parkinson’s disease currently affects around 150,000 people in France. Deep Brain Stimulation (DBS) is the most commonly performed surgical treatment for Parkinson's, but it's not for everyone. DBS therapy is currently approved in many locations across the world, including the United States and Europe, as a treatment for the disabling symptoms of essential tremors, and recently, the long-standing Parkinson's disease. Thus, owing to the all above-mentioned factors, the market is expected to witness high growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
Europe Neurostimulation Devices Industry Overview
The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some of the market players are Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, Nevro Corporation, NeuroSigma Inc., The Magstim Company Limited, Neuronetics, and Renishaw PLC.
Europe Neurostimulation Devices Market Leaders
-
Medtronic PLC
-
Abbott Laboratories
-
The Magstim Company Limited
-
Renishaw PLC
-
Boston Scientific Corporation
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Europe Neurostimulation Devices Industry Segmentation
As per the scope of this report, neurostimulation therapies include invasive and noninvasive approaches that involve the application of electrical stimulation, to drive neural function within a circuit. The market is segmented by technology, application, and geography.
| By Technology | Internal Neuromodulation | Spinal Cord Stimulation (SCS) | |
| Deep Brain Stimulation (DBS) | |||
| Vagus Nerve Stimulation (VNS) | |||
| Sacral Nerve Stimulation (SNS) | |||
| Gastric Electrical Stimulation (GES) | |||
| External Neuromodulation (Non-Invasive) | Transcutaneous Electrical Nerve Stimulation (TENS) | ||
| Transcranial Magnetic Stimulation (TMS) | |||
| Respiratory Electrical Stimulation (RES) | |||
| By Application | Parkinson's disease | ||
| Epilepsy | |||
| Depression | |||
| Dystonia | |||
| Pain Management | |||
| Other Applications | |||
| Geography | Europe | Germany | |
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
Need A Different Region or Segment?
Customize Now
Europe Neurostimulation Devices Market Research FAQs
What is the current Europe Neurostimulation Market size?
The Europe Neurostimulation Market is projected to register a CAGR of 6.1% during the forecast period (2025-2030)
Who are the key players in Europe Neurostimulation Market?
Medtronic PLC, Abbott Laboratories, The Magstim Company Limited, Renishaw PLC and Boston Scientific Corporation are the major companies operating in the Europe Neurostimulation Market.
What years does this Europe Neurostimulation Market cover?
The report covers the Europe Neurostimulation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Europe Neurostimulation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Europe Neurostimulation Industry Report
Statistics for the 2025 Europe Neurostimulation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Europe Neurostimulation analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
